Researcher identifies breast cancer fighting hormone

May 24, 2013

Transformative research from Western University has identified new hormones in the body which may suppress breast cancer and stimulate the regression of breast tumors.

The findings, led by renowned Western biology professor John P. Wiebe, have been published by Breast Cancer Research.

Of the nearly 1.4 million new cases of breast cancer diagnosed each year, up to half are characterized as hormone receptor negative, meaning they lack estrogen receptors (ER) and/or (PR).

Wiebe explains that receptors are molecules that can link to substances, such as hormones and then stimulate or inhibit the machinery of a cell – not unlike the way a key fits into a lock.

According to Wiebe, cancer patients with receptor-negative tumors do not respond to current steroid hormone-based therapies (such as tamoxifen) and can only be treated with chemotherapy or radiation.

"They generally have significantly higher risk of mortality compared to patients with tumors that are ER and/or PR positive," says Wiebe. "What causes these receptor-negative cancers has been little studied and was not understood and there are no therapies other than chemotherapy or radiation treatments."

Wiebe and his team identified for the first time in human that the progesterone metabolites 5α-dihydroprogesterone (5αP) and 3α-dihydroprogesterone (3αHP), respectively, exhibit pro-cancer and anti-cancer effects on receptor-negative human and investigated their ability to control initiation, growth and regression of ER/PR-negative human breast cell tumors.

"Many endocrinologists still consider these metabolites waste product but they're not. We've found that they are potent hormones that can play a vital role in the fight against ," offers Wiebe, who will share the findings in a Featured Presentation at the Endocrine (ENDO) Society Annual Meeting and Expo in San Francisco in June.

"Our findings provide unequivocal evidence that 5αP and 3αHP deserve to be considered as active hormones in their own right, rather than inactive waste products, and that they need to be considered in the development of new approaches to prevention, detection and treatment of breast cancers," says Wiebe.

The new findings also provide the first explanation for the cause and potential regulation of receptor-negative breast cancers.

Related Stories

New target, new drug in breast cancer

June 4, 2012

Many breast cancers depend on hormones including estrogen or progesterone for their survival and proliferation. Eight years of lab work at the University of Colorado Cancer Center and elsewhere suggest that the androgen (AR) ...

Breast cancer recurrence defined by hormone receptor status

October 1, 2012

Human epidermal growth factor (HER2) positive breast cancers are often treated with the same therapy regardless of hormone receptor status. New research published in BioMed Central's open access journal Breast Cancer Research ...

Clinical trial hits new target in war on breast cancer

December 3, 2012

Breast cancers are defined by their drivers – estrogen and progesterone receptors (ER and PR) and HER2 are the most common, and there are drugs targeting each. When breast cancer has an unknown driver, it also has fewer ...

Recommended for you

Strange circular DNA may offer new way to detect cancers

July 30, 2015

Strange rings of DNA that exist outside chromosomes are distinct to the cell types that mistakenly produced them, researchers have discovered. The finding raises the tantalizing possibility that the rings could be used as ...

New treatment options for a fatal leukemia

July 27, 2015

In industrialized countries like in Europe, acute lymphoblastic leukemia is the most common form of cancer in children. An international research consortium lead by pediatric oncologists from the Universities of Zurich and ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.